Please assess the completion status of the following clinical trial:

Trial Title: A Clinical Study, Randomized, Double-blind, Placebo-controlled, Single Dose Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Healthy Male between 20 and 45 years of age at the time of screening~2. Subjects with body mass index (BMI) between 20 and 27 at the time of screening~3. Agree to continue to use a medically reliable dual contraception and not to donate sperm until 30th days of study completion~4. Capable of giving written informed consent, willing to participate in this clinical trial, and willing to comply with all study requirements~Exclusion Criteria:~1. History of liver, kidney, respiratory, musculoskeletal, endocrinologic, neuropsychiatric, hemato-oncologic, or cardiovascular problem(s).~2. History of gastrointestinal problem (e.g. Crohn's disease, gastro-intestinal ulcer) which is affect to absorption within 6 months from screening~3. History of hypersensitivity or clinically significant adverse drug reaction(s) to the LCB01-0371, same class of the study drugs (linezolid), or other drugs including aspirin and antibiotics.~4. History of drug abuse or positive result at urine drug screening test~5. AST, ALT, r-GT, billirubin(total) values over than 1.5 times of ULN

- Gender: MALE
- Minimum Age: 20 Years
- Maximum Age: 45 Years
- Healthy Volunteers: t

Study Arms:
- LCB01-0371 (Type: EXPERIMENTAL): active
- Linezolid (Type: EXPERIMENTAL): comparator

Based on this trial design, predict the completion outcome and termination type (if applicable).